- Investors & Media
- Investors & Media
- Contact Us
Kamada today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”).
Kamada announced today financial results for the three and 12-months
ended December 31, 2018.
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test.
Top-line Results Anticipated in H2 2019
Kamada management will host an investment community conference call on Tuesday, February 12 at 8:30am Eastern Time to discuss these results and answer questions.
announced today the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development. She will oversee all of Kamada’s R&D and IP activities, and report directly to Amir London, Kamada’s Chief Executive Officer.
Dr. Ayalon will succeed Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is retiring next month.
Kamada announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million.
Kamadad announced today financial results for the three and nine months ended September 30, 2018.
Kamada announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. He will lead Kamada’s business development and strategic commercial activities, with a focus on advancing market opportunities for the Company’s products. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.
Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.
As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.